



Aureus Pharma Releases AurSCOPE® hERG Channel a New Database Related to Cardiotoxicity

Paris, France (March 1, 2005) - Aureus Pharma announced today the release of a new AurSCOPE® database for the hERG channel. The hERG channel is of major importance to the pharmaceutical industry today as interaction of some drugs with this channel has led to cardiotoxicity and recently several major pharmaceuticals have been pulled from the market due to hERG related safety concerns.

The AurSCOPE hERG Channel database contains up to date data including all published structure activity relationships concerning hERG-ligand interactions. “Researchers use Aureus Pharma’s knowledge base to better predict the potential hERG related side effects of a compound,” said Dr. André Michel, Aureus Pharma’s CEO. “Our latest AurSCOPE database will greatly complement a company’s proprietary data in addressing this critical safety issue.”

This new database strengthens the product portfolio of Aureus Pharma which now includes databases for G-Protein Coupled Receptors, Ion Channels, and ADME/Drug-Drug Interactions.

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solution provider for the life sciences industry. Aureus Pharma accelerates new drug discovery with innovative products combining computerized knowledge management systems with quantitative biological activity. For further information on how Aureus Pharma helps researchers turn data into discovery visit www.aureus-pharma.com

Contact

Mary E. Donlan, Ph. D.
Director of Marketing & Sales
+33 1 40 18 57 57
mary.donlan@aureus-pharma.com

TEL (33) (0)1.40.18.57.57 – FAX : (33) (0)1.40.18.57.58

S.A. AU CAPITAL DE 58 427 € - SIÈGE SOCIAL : 174-178 QUAI DE JEMMAPES – 75010 PARIS
N° TVA INTRACOMMUNAUTAIRE : FR 75429083207 - SIRET : 429 083 207 00028 – APE 731Z